All In MedTech

Device Trial Radar · NCT04409561

Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

A Study to Establish a Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

Last checked: Nov 19, 2026Latest source record: Mar 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

150

Actual

Start

Nov 15, 2021

Primary completion

Nov 15, 2021

Study completion Jan 15, 2022

Sponsor

Lead sponsor
Abionic SANot on our public-company list
Sponsor type
Industry
Collaborators
Boston Biomedical Associates; Ocean State Clinical Coordinating Center
First posted
Jun 1, 2020

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

This is a single center, prospective, biomarker-result-blinded observational study evaluating immunoassay measurements of pancreatic stone protein (PSP) performed on Abionic's abioSCOPE device with the PSP assay on generally healthy adults representative of the US population.

Conditions

  • Sepsis
  • Septic Shock
  • Healthy

Interventions

  • Blood collectionDevice

    9 mL K3-EDTA anticoagulated venous whole blood and 9 mL lithium heparin anticoagulated venous whole blood will be collected, processed in plasma and stored until the shipment to the sponsor for PSP measurement on the abioSCOPE device with IVD CAPSULE PSP kits

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of reference range interval of PSPTime frame: Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mercy Health St. Vincent

    Toledo, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.